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abstract
PURPOSE Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with
standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after
completion of standard chemotherapy in patients with early TNBC.
PATIENTS AND METHODS Eligible patients were those with operable, node-positive—or node negative with tumor
1 cm or greater—TNBC, with prior anthracycline- and/or taxane-containing chemotherapy. After central
confirmation of TNBC status by immunohistochemistry, patients were randomly assigned to either capecitabine
or observation. Stratification factors included institution, prior taxane-based therapy, involved axillary lymph
nodes, and centrally determined phenotype (basal v nonbasal, according to cytokeratins 5/6 and/or epidermal
growth factor receptor positivity by immunohistochemistry). The primary objective was to compare disease-free
survival (DFS) between both arms.
RESULTS Eight hundred seventy-six patients were randomly assigned to capecitabine (n = 448) or ob-
servation (n = 428). Median age was 49 years, 55.9% were lymph node negative, 73.9% had a basal
phenotype, and 67.5% received previous anthracyclines plus taxanes. Median length of follow-up was 7.3
years. DFS was not significantly prolonged with capecitabine versus observation [hazard ratio (HR), 0.82;
95% CI, 0.63 to 1.06; P = .136]. In a preplanned subgroup analysis, nonbasal patients seemed to derive
benefit from the addition of capecitabine with a DFS HR of 0.53 versus 0.94 in those with basal phenotype
(interaction test P = .0694) and an HR for overall survival of 0.42 versus 1.23 in basal phenotype (in-
teraction test P = .0052). Tolerance of capecitabine was as expected, with 75.2% of patients completing the
planned 8 cycles.
CONCLUSION This study failed to show a statistically significant increase in DFS by adding extended capecitabine
to standard chemotherapy in patients with early TNBC. In a preplanned subset analysis, patients with nonbasal
phenotype seemed to obtain benefit with capecitabine, although this will require additional validation.
J Clin Oncol 38:203-213. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Early triple-negative breast cancer (TNBC) can be
cured with local–regional therapy plus adjuvant
chemotherapy, usually anthracycline- and/or taxane-
based combinations. However, despite these thera-
pies, a proportion of patients eventually experience
relapse and die. A recent analysis of data from the
National Cancer Institute SEER reported a 3-year re-
lapse rate of approximately 8%, 15%, and 40% for
patients with stages I, II, and III TNBC,1 respectively;
therefore, new adjuvant options are necessary to im-
prove the prognosis of this breast cancer subtype.
Capecitabine is an oral prodrug of fluorouracil ap-
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patients with prior progression after anthracyclines and
taxanes and is therefore partially non–cross resistant with
these two classes of agents.2 On the basis of this concept,
we carried out a trial in which capecitabine was sequentially
added to standard (neo)adjuvant chemotherapy in oper-
able TNBC to explore the ability of the drug to reduce the
rate of relapse and increase the survival of this disease.
PATIENTS AND METHODS
The GEICAM/2003-11_CIBOMA/2004-01 trial is an open-
label, randomized phase III study that was conducted in
compliance with the International Council for Harmoniza-
tion Good Clinical Practice guidelines and the Declaration
of Helsinki. The study was reviewed and approved by the
independent ethics committees or institutional review
boards of all participating institutions. Written informed
consent was obtained from all patients before any study-
related procedures were performed.
Patient Eligibility
Eligible patients included women with hormone recep-
tor–negative (immunohistochemistry staining of estrogen
and progesterone receptors , 1%) and human epidermal
growth factor 2–negative operable breast cancer, with in-
vasive adenocarcinoma histologically confirmed. Patients
had received 6 to 8 cycles of standard anthracycline- and/
or taxane-containing chemotherapy in the (neo)adjuvant
setting, followed by radiation therapy according to in-
stitutional guidelines. In the case of node-negative dis-
ease, 4 cycles of doxorubicin and cyclophosphamide
were allowed. Eligible patients were those with ipsilateral
axillary node involvement classified as pN1a, pN2a,




   Allocated to intervention





   Not meeting inclusion criteria
   Refused participation






   Allocated to intervention
   (ITT population)
(n = 428)
Early discontinuation of protocol therapy
   Patient refusal
   Unacceptable toxicity
   Disease recurrence
   Interruption of capecitabine >3 weeks
   Death
   Protocol deviation
   Lost to follow-up
   Other reason
(n = 111)  
(n = 33)  
(n = 34)  
(n = 9)  
(n = 11)  
(n = 4)*
(n = 5)  
(n = 1)  
(n = 14)  
Discontinuation in observation arm
   Patient refusal
   Unacceptable residual toxicity
   Disease recurrence
   Death
   Protocol deviation
   Lost to follow-up
   Second primary malignancy
   Other reason
  
(n = 6)      
(n = 1)      
(n = 13)      
(n = 1)      
(n = 1)      
(n = 1)      
(n = 5)      
Observation arm
   Received allocated intervention
   (Safety population)  
(n = 425)
Capecitabine arm
   Received allocated intervention




FIG 1. All patients enrolled (N = 876) were included in the efficacy analyses. All patients who had received at least 1 cycle of study
treatment (n = 861) were evaluated for safety. Safety population: In the capecitabine arm, all patients who have completed at least one
cycle of study treatment and in the observation arm, all patients with a follow-up period$ 14 days. *Reasons of death on these patients:
psychiatric disorder, cerebral hemorrhage, septic shock secondary to respiratory infection and stroke (not related with capecitabine).
†Discontinuation of initial follow-up period (equivalent to treatment period in capecitabine arm). ‡Reasons of death on these patients:
acute myocardial infarction and pulmonary sepsis.
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nodes—according to the American Joint Committee on
Cancer 2002 staging system. Patients without axillary node
involvement (N0) were also eligible provided the primary
tumor measured 1 cm or greater in diameter. Patients were
ineligible in the case of bilateral invasive breast cancer,
absence of surgical treatment with curative intent, resection
of fewer than 6 lymph nodes when axillary lymph node
dissection was performed, or pregnancy or breastfeeding.
Triple-negative and basal versus nonbasal status were
determined centrally by a GEICAM Spanish Breast Cancer
Group pathologist (F.R.). Tumors with any staining for
epidermal growth factor receptor and/or cytokeratins 5/6
were considered basal. Patients with no staining for both
biomarkers were considered nonbasal.3
Study Procedures
Baseline assessments performed before patient randomi-
zation in centrally confirmed eligible patients included
mammography, chest radiography, abdominal ultraso-
nography and/or computed tomography (CT), bone scan (if
bone pain or increased alkaline phosphatase), and bone
X-ray (if suspicious lesions on the bone scan). Hematology,
biochemistry, and pregnancy test—potentially fertile
women only—were also completed before randomization.
Eligible patients were stratified according to basal status
(yes v no), institution, number of axillary lymph nodes
(0 v 1-3 v 4 or more), and type of adjuvant chemotherapy
(anthracyclines plus taxanes v anthracyclines alone). Pa-
tients were randomly assigned on a one-to-one basis to
eight cycles of capecitabine 2,000 mg/m2 (1,000 mg/m2
administered orally two times per day) on days 1 to 14 every
3 weeks, or observation. Two dose reductions were
permitted—75% and 50% of initial dose—on the basis of
hematologic or nonhematologic adverse events (AEs)
observed. Randomization was centralized at GEICAM
headquarters.
AEs were assessed during the study period and graded
according to National Cancer Institute Common Termi-
nology Criteria for Adverse Events version 3.0. Serious AEs
(SAEs) were reported during the study treatment and within
30 days of the end of this time period.
Physical examination, menopausal status, and presence of
amenorrhea were assessed at baseline, at every cycle
during the treatment period, every 3 months during years 1
to 2, every 6 months during years 3 to 5, and yearly af-
terward. Mammograms were performed yearly. Chest
X-ray, abdominal ultrasounds, CT scan, or bone scans were
performed if clinically indicated in the case of suspicion of
disease recurrence. A complete follow-up on vital status
was obtained until April 11, 2018, for all patients.
Statistical Analysis
Primary end point was disease-free survival (DFS), which
was measured from the date of random assignment in the
intent-to-treat (ITT) population to locoregional or distant
TABLE 1. Patients’ Demographics and Baseline Disease Characteristics According
to Study Arm (intention-to-treat population)
Demographic or Characteristic
Capecitabine Arm
(n = 448), No. (%)
Observation Arm
(n = 428), No. (%)
Median age, years (range) 50.0 (20.0-79.0) 49.0 (23.0-82.0)
Region
Spain 272.0 (60.7) 260.0 (60.7)
Latin America 176.0 (39.3) 168.0 (39.3)
Race
White 313.0 (69.9) 309.0 (72.2)
Hispanic 107.0 (23.9) 97.0 (22.7)
African American 16.0 (3.6) 11.0 (2.6)
Other 12.0 (2.7) 11.0 (2.6)
Karnofsky performance status
100 383.0 (85.5) 344.0 (80.4)
90 57.0 (12.7) 67.0 (15.7)
80 8.0 (1.8) 17.0 (4.0)
Menopausal status at diagnosis
Premenopausal 136.0 (30.4) 140.0 (32.7)
Postmenopausal 312.0 (69.6) 288.0 (67.3)
Histologic type
Invasive ductal carcinoma 395.0 (88.2) 369.0 (86.2)
Invasive lobular carcinoma 9.0 (2.0) 10.0 (2.3)
Other 44.0 (9.8) 49.0 (11.4)
Histologic grade
G1 15.0 (3.3) 12.0 (2.8)
G2 82.0 (18.3) 81.0 (18.9)
G3 323.0 (72.1) 299.0 (69.9)
GX 28.0 (6.3) 36.0 (8.4)
Phenotype by IHC
Basala 329.0 (7,373.4) 318.0 (7,474.3)
Nonbasal 119.0 (2,626.6) 110.0 (2,525.7)
Stage at diagnosis (AJCC 2002)
I 62.0 (13.8) 74.0 (17.3)
II 270.0 (60.3) 271.0 (63.3)
III 106.0 (23.7) 80.0 (18.7)
Not available 10.0 (2.2) 3.0 (0.7)
Nodal status
Negative 244.0 (54.5) 242.0 (56.5)
1-3 positive nodes 121.0 (27.0) 124.0 (29.0)
$ 4 positive nodes 77.0 (17.2) 61.0 (14.3)
Missing data 6.0 (1.3) 1.0 (0.2)
Type of prior chemotherapy
Adjuvant (only) 353.0 (78.8) 352.0 (82.2)
Neoadjuvant (6 adjuvant) 89.0 (19.9) 75.0 (17.5)
Missing data 6.0 (1.3) 1.0 (0.2)
(continued on following page)
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recurrence, second primary malignancy, or death date,
whichever occurred first. Secondary end points included
5-year DFS, overall survival (OS), safety, and analyses by
subgroups and of biomarkers.
According to the GEICAM El Álamo registry,4 estimated
5-year DFS for a similar population of patients with TNBC
was 64.7%. The aim was to detect an increase in DFS
to 73.7% with capecitabine, corresponding to a hazard ratio
(HR) of 0.701 with a power of 80% using a two-tailed log-
rank test at 0.05 and considering 4 years of recruitment and
3 years of follow-up. Two hundred fifty-five events were
projected and 834 eligible patients were needed. Assuming
a drop-out rate of 5%, 876 patients were to be enrolled—438
patients in each arm. The sample size calculation was
performed using EAST version 5.2.
The initial protocol established the main DFS analysis to
be performed after 255 events; however, the number of
DFS events was much lower than expected and the
steering committee of the study—with the advice of the
independent data monitoring committee—therefore de-
cided to perform the analysis after a median follow-up of
more than 7 years after a total of 225 events and when the
rate of annual recurrences was low in both arms of
the study.
We used the Kaplan-Meier limit-product method to esti-
mate DFS and OS and comparison between the two study
arms was performed using the stratified log-rank test using
the stratification factors [basal status, number of axillary
lymph nodes, and type of (neo)adjuvant chemotherapy]. All
tests of hypotheses were two sided. In addition, we per-
formed a multivariable Cox proportional hazard model
analysis for DFS and OS to adjust for major prognostic
factors: age, menopausal status, histopathologic findings,
tumor size, disease stage, type of surgery, region, and the
stratification factors for randomization.
The safety analysis was performed in all patients who had
received at least 1 cycle of study treatment. The worst AE
grade per category for each patient was reported.
RESULTS
Study Patients
Between October 2006 and September 2011, 876 patients
were recruited across 80 institutions in 8 countries (Spain,
Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Ven-
ezuela; Fig 1).
Demographics and baseline disease characteristics were
balanced, with no statistical differences between the two
arms but with a slightly numerically higher proportion of
poor prognosis features in the capecitabine arm (Table 1).
The majority of patients were white and postmenopausal,
and median age was 49 years. Most frequently, tumors
were of grade 3 (71%), basal phenotype (73.9%), stage II at
diagnosis (61.8%), and node negative (55.9%). Small
differences were found in relation to disease stage at
diagnosis—based on American Joint Committee on Cancer
2002—and the number of involved lymph nodes.
Most patients in both arms had received adjuvant che-
motherapy with anthracyclines and taxanes (67.5%), had
breast-conservative surgery (54.7%) and axillary lymph
node dissection with or without sentinel lymph node biopsy
(74.8%), and received radiation therapy (79.7%).
Drug Exposure and Discontinuations
Of patients who were assigned to capecitabine, 75.2%
(n = 337) completed 8 cycles of treatment. Median
number of cycles was 8 (range, 1 to 8 cycles). A few pa-
tients (n = 12; 2.7%) did not complete at least 1 cycle of
treatment and were excluded from the safety analysis as
per protocol requirement. Four percent (n = 18) of patients
completed 1 cycle of capecitabine, 10.3% (n = 46) of
patients completed 2 to 4 cycles, and 7.8% (n = 35) of
patients completed 5 to 7 cycles. Median dose intensity was
86.3% (range, 0.86% to 136.2%). Dose intensity rate was
between 110% and 80% in 55.8% (n = 250) of patients
and less than 75% in 33.5% (n = 150) of patients. Five
patients were reported to have a dose intensity rate between
110%and 136.2%. In four of these patients, it was because
of a mistake or rounding the capecitabine dose and in the
TABLE 1. Patients’ Demographics and Baseline Disease Characteristics According
to Study Arm (intention-to-treat population) (continued)
Demographic or Characteristic
Capecitabine Arm
(n = 448), No. (%)
Observation Arm
(n = 428), No. (%)
pCR in patients with neoadjuvant
chemotherapyb
22.0 (24.7) 19.0 (25.3)
Chemotherapy regimen
Anthracyclines based 147.0 (32.8) 138.0 (32.2)
Anthracyclines and taxanes based 301.0 (67.2) 290.0 (67.8)
Breast surgery
Conservative 237.0 (52.9) 242.0 (56.5)
Mastectomy 205.0 (45.8) 185.0 (43.2)
Missing data 6.0 (1.3) 1.0 (0.2)
Axillary surgery
ALND 6 SLNB 349.0 (78.0) 306.0 (71.5)
SLNB 99.0 (22.1) 122.0 (28.5)
Radiation therapy
Yes 352.0 (78.6) 346.0 (80.8)
No 91.0 (20.3) 81.0 (18.9)
Unknown 5.0 (1.1) 1.0 (0.2)
NOTE. Data are presented as No. (%) except where otherwise noted.
Abbreviations: AJCC, American Joint Committee on Cancer; ALND, axillary
lymph node dissection; IHC, immunohistochemistry; pCR, pathologic complete
response; SLNB, sentinel lymph node biopsy.
aBasal phenotype: cytokeratins 5/6-positive and/or epidermal growth factor
receptor positive.
bpCR in the breast and ipsilateral axilla.
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FIG 2. (A, C, D) Disease-free survival (DFS) and (B, E, F) overall survival (OS) Kaplan-Meier curves on the intention-to-treat population and subpopulations
based on the immunohistochemistry phenotype.
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fifth patient the reason is unknown. Dose reductions of
capecitabine were reported in 161 patients (36.9%).
Main reasons for discontinuation of capecitabine (n = 97)
were patient refusal, unacceptable toxicity, disease re-
currence, or interruption of capecitabine for more than
3 weeks because of AEs (Fig 1).
Efficacy
At the time of data cutoff, median follow-up was 7.4 years
and 7.2 years in the capecitabine and observation arms,
respectively. A total of 225 events were observed, 105
(23.4%) in the capecitabine arm and 120 (28%) in the
observation arm. In the ITT analysis (n = 876), results of the
Cox proportional hazards regression model did not dem-
onstrate a statistically significant difference in DFS between
the capecitabine and observation arms (unadjusted HR,
0.82; 95% CI, 0.63 to 1.06; P = .136; adjusted HR
according to stratification factors, 0.79; 95% CI, 0.61 to
1.03; P = .082; and fully adjusted HR, 0.77; 95% CI, 0.59
to 1.00; P = .051). Five-year DFS rates were 79.6% (95%
CI, 75.8% to 83.4%) in the capecitabine arm and 76.8%
(95% CI, 72.7% to 80.9%) in the observation arm.
Figure 2A shows the Kaplan-Meier curves for DFS. In
addition, there was no statistically significant difference in
OS between study arms (unadjusted HR, 0.92; 95% CI,
0.66 to 1.28; P = .623; adjusted HR according to strati-
fication factors, 0.88; 95% CI, 0.64 to 1.23; P = .4562; and
fully adjusted HR, 0.86; 95% CI, 0.6262 to 1.20; P = .371).
Five-year OS rates were 86.2% (95% CI, 82.9% to 89.4%)
in the capecitabine arm and 85.9% (95% CI, 82.4% to
89.3%) in the observation arm. Figure 2B shows the
Kaplan-Meier curves for OS.
An exploratory subgroup analysis for DFS in the ITT pop-
ulation (Fig 3) showed similar treatment effects by men-
opausal status (pre- v postmenopausal), phenotype (basal
v nonbasal), nodal status (negative v 1 to 3 positive nodes, 4
or more positive nodes), type of previous CT scan (neo-
adjuvant v adjuvant), prior administration of taxanes (yes v
no) and region (Spain v Latin America). Patients with
a nonbasal phenotype had a statistically significant in-
crease in DFS (HR, 0.53; 95% CI, 0.31 to 0.91; P = .022)
and OS (HR, 0.42; 95% CI, 0.21 to 0.81; P = .0095) with
capecitabine. Five-year DFS rates were 82.6% (95% CI,
75.7% to 89.5%) with capecitabine and 72.9% (95% CI,
64.4% to 81.3%) in the observation arm. Five-year OS rates
were 89.5% (95% CI, 83.9% to 95.1%) with capecitabine
and 79.6% (95% CI, 71.7% to 87.4%) in the observation
arm. The interaction tests treatment/nonbasal status had
Subgroup Analysis of DFS
HR (95% CI)No. of EventsHRNo. of Patients (%)Subgroup
0.819 (0.630 to 1.065)
0.686 (0.408 to 1.153)
0.867 (0.639 to 1.176)
0.942 (0.697 to 1.272)
0.530 (0.307 to 0.913)
1.006 (0.586 to 1.727)
0.747 (0.552 to 1.012)
0.884 (0.551 to 1.418)
0.798 (0.583 to 1.093)
0.687 (0.456 to 1.037)
0.800 (0.496 to 1.289)
0.937 (0.566 to 1.550)
0.750 (0.534 to 1.053)
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FIG 3. Subgroup analysis for disease-free survival (DFS) on the intention-to-treat (ITT) population. HR, hazard ratio.
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adjusted P values of .0694 for DFS and .0052 for OS.
Figures 2C and 2D show the Kaplan-Meier curves for DFS
and OS, respectively, in the basal and nonbasal phenotype
subpopulations.
The number and type of DFS events in the overall and
nonbasal populations are shown in Table 2. Of note, in the
nonbasal subpopulation, and in agreement with DFS and
OS data, DFS events were more frequent in the observation
arm [30.9% (n = 34)] compared with the capecitabine arm
[17.6% (n = 21)]. Remarkably, in this subtype the re-
duction of DFS events with capecitabine wasmainly a result
of distant relapses, particularly in liver, CNS, and lymph
nodes. Demographics and baseline disease characteristics
according to basal versus nonbasal phenotype are included
in Table 3.
Safety
Safety was assessed in 861 patients of the study pop-
ulation: 436 patients (97.3%) in the capecitabine arm and
425 patients (99.3%) in the observation arm. AEs were
reported in 95.4% (n = 416) of patients in the capecitabine
arm and 63.8% (n = 271) in the observation arm (Table 4).
In addition, 40.6% (n = 177) and 15.5% (n = 66) of
patients had AEs of grade 3 or greater in the capeci-
tabine and observation arms, respectively. With cape-
citabine, 92.4% (n = 403) of patients had AEs related to
study treatment, and in 30% (n = 131) of patients these
AEs were of grade 3 or greater. Patients who experi-
enced at least one SAE were 5.3% (n = 23) in the
capecitabine arm and 1.4% (n = 6) in the observation
arm. In addition, there were a few patients with SAEs that
caused death: 1.1% (n = 5) in the capecitabine arm and
0.5% (n = 2) in the observation arm. Two deaths in the
capecitabine arm were probably related to study treat-
ment according to investigator’s criteria. These SAEs
included one case of septic shock in the absence of
neutropenia and one case of grade 4 hyperbilirubinemia
and systemic organ failure.
TABLE 2. Disease-Free Survival Events in Overall Population (intention to treat) and Nonbasal Phenotype Subpopulation
Variable
Overall Population, No. (%) Nonbasal Population, No. (%)
Capecitabine (n = 448) Observation (n = 428) Capecitabine (n = 119) Observation (n = 110)
Event
No event 343.0 (76.6) 308.0 (72.0) 98.0 (82.4) 76.0 (69.1)
Disease recurrence 78.0 (17.4) 94.0 (22.0) 18.0 (15.1) 24.0 (21.8)
Death 14.0 (3.1) 10.0 (2.3) 2.0 (1.7) 3.0 (2.7)
Second primary malignancy 13.0 (2.9) 16.0 (3.7) 1.0 (0.8) 7.0 (6.4)
Type of event
Any DFS event 105.0 (23.4) 120.0 (28.0) 21.0 (17.6) 34.0 (30.9)
Distant recurrence (any) 64.0 (14.3) 66.0 (15.4) 13.0 (10.9) 18.0 (16.4)
Contralateral invasive breast cancer 12.0 (2.7) 14.0 (3.3) 3.0 (2.5) 2.0 (1.8)
Ipsilateral breast cancer recurrence 5.0 (1.1) 12.0 (2.8) 2.0 (1.7) 3.0 (2.7)
Locoregional invasive recurrence (after
mastectomy)
0.0 4.0 (0.9) 0.0 2.0 (1.8)
Regional invasive recurrence (after BCS) 3.0 (0.7) 1.0 (0.2) 0.0 0.0
Disease recurrence (unknown location) 1.0 (0.2) 0.0 0.0 0.0
Second primary malignancy (nonbreast) 6.0 (1.3) 13.0 (3.0) 1.0 (0.8) 6.0 (5.5)
Death 14.0 (3.1) 10.0 (2.3) 2.0 (1.7) 3.0 (2.7)
Location of distant recurrence
Lung 31.0 (6.9) 29.0 (6.8) 7.0 (5.9) 6.0 (5.5)
Bone 19.0 (4.2) 19.0 (4.4) 4.0 (3.4) 5.0 (4.5)
Lymph nodes 16.0 (3.6) 18.0 (4.2) 1.0 (0.8) 4.0 (3.6)
Liver 13.0 (2.9) 20.0 (4.7) 2.0 (1.7) 6.0 (5.5)
CNS 13.0 (2.9) 15.0 (3.5) 3.0 (2.5) 6.0 (5.5)
Skin 2.0 (0.4) 0.0 0.0 0.0
Brain 2.0 (0.4) 1.0 (0.2) 0.0 0.0
Other 9.0 (2.0) 12.0 (2.8) 2.0 (1.7) 3.0 (2.7)
NOTE. The location of distant recurrence is not exclusive. Patients may have several organs involved as part of their distant recurrence.
Abbreviations: BCS, breast-conserving surgery; DFS, disease-free survival.
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DISCUSSION
Our study failed to show a statistically significant im-
provement in DFS by adding 8 cycles of extended cape-
citabine to standard (neo)adjuvant chemotherapy for
operable TNBC after a median follow-up of more than
7 years. Adjusted HR, considering the stratification factors,
was 0.79 (P = .082); therefore, the study was formally
negative in accordance with the statistical assumption
made when the trial was designed. The role of capecitabine
in combination with other drugs as adjuvant therapy of
operable breast cancer is still unclear.5-7 As a single agent,
adjuvant capecitabine was inferior to standard adjuvant
therapy—either cyclophosphamide, methotrexate, fluoro-
uracil; or doxorubicin plus cyclophosphamide—in patients
with breast cancer age 65 years or older.8 A recent meta-
analysis of (neo)adjuvant capecitabine trials, including
8 trials and 9,302 patients, found that globally, capecitabine
did not improve DFS9; however, in trials in which capecitabine
TABLE 3. Patients’ Demographics and Baseline Disease Characteristics According to Basal Versus Nonbasal Phenotype (intention-to-treat population)
Demographic or Characteristic









Median age, years (range) 50.0 (24.0-79.0) 50.0 (20.0-75.0) 49.0 (26.0-82.0) 48.0 (23.0-74.0)
Region
Spain 202.0 (61.4) 70.0 (58.8) 189.0 (59.4) 71.0 (64.5)
Latin America 127.0 (38.6) 49.0 (41.2) 129.0 (40.6) 39.0 (35.5)
Menopausal status at diagnosis
Premenopausal 105.0 (31.9) 31.0 (26.1) 107.0 (33.6) 33.0 (30.0)
Postmenopausal 224.0 (68.1) 88.0 (73.9) 211.0 (66.4) 77.0 (70.0)
Histologic grade
G1 10.0 (3.0) 5.0 (4.2) 9.0 (2.8) 3.0 (2.7)
G2 62.0 (18.8) 20.0 (16.8) 55.0 (17.3) 26.0 (23.6)
G3 238.0 (72.3) 85.0 (71.4) 235.0 (73.9) 64.0 (58.2)
GX 19.0 (5.8) 9.0 (7.6) 19.0 (6.0) 17.0 (15.5)
Stage at diagnosis (AJCC 2002)
I 50.0 (15.2) 12.0 (10.1) 59.0 (18.6) 15.0 (13.6)
II 201.0 (61.1) 69.0 (58.0) 200.0 (62.9) 71.0 (64.5)
III 73.0 (22.2) 33.0 (27.7) 56.0 (17.6) 24.0 (21.8)
Not available 5.0 (1.5) 5.0 (4.2) 3.0 (0.9) 0.0
Nodal status
Negative 179.0 (54.4) 65.0 (54.6) 187.0 (58.8) 55.0 (50.0)
1-3 positive nodes 90.0 (27.4) 31.0 (26.1) 88.0 (27.7) 36.0 (32.7)
$ 4 positive nodes 57.0 (17.3) 20.0 (16.8) 42.0 (13.2) 19.0 (17.3)
Missing data 3.0 (0.9) 3.0 (2.5) 1.0 (0.3) 0.0
Type of prior chemotherapy
Adjuvant (only) 273.0 (83.0) 80.0 (67.2) 269.0 (84.6) 83.0 (75.5)
Neoadjuvant (6 adjuvant) 53.0 (16.1) 36.0 (30.3) 48.0 (15.1) 27.0 (24.5)
Missing data 3.0 (0.9) 3.0 (2.5) 1.0 (0.3) 0.0
pCR in patients with neoadjuvant chemotherapyb 12.0 (22.6) 10.0 (27.8) 12.0 (25.0) 7.0 (25.9)
Chemotherapy regimen
Anthracyclines based 118.0 (35.9) 29.0 (24.4) 109.0 (34.3) 29.0 (26.4)
Anthracyclines and taxanes based 211.0 (64.1) 90.0 (75.6) 209.0 (65.7) 81.0 (73.6)
NOTE. Data are presented as No. (%) except where otherwise noted.
Abbreviations: AJCC, American Joint Committee on Cancer; pCR, pathologic complete response.
aBasal phenotype: cytokeratins 5/6 positive and/or epidermal growth factor receptor positive; and nonbasal phenotype: cytokeratins 5/6 and epidermal
growth factor receptor negative.
bpCR in the breast and ipsilateral axilla.
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was added to standard adjuvant chemotherapy (in contrast
to those trials in which capecitabine replaced standard
agents), a significant DFS advantage was found. Of note, in
this meta-analysis the benefit of adding capecitabine to
standard chemotherapy was mainly observed in patients
with TNBC. The GEICAM-CIBOMA study added sequential
capecitabine to standard (neo)adjuvant chemotherapy in
patients with operable TNBC but was unable to show
a statistically significant improvement in DFS in the overall
population. The results of our study were therefore ap-
parently different from those of the meta-analysis and, in
particular, from those of the the Capecitabine for Residual
Cancer as Adjuvant Therapy (CREATE-X) trial,10 which
addressed a similar question but in a population at higher
risk of relapse. The CREATE-X trial randomly assigned
patients with breast cancer with residual disease at surgery
after standard neoadjuvant chemotherapy to 6 to 8 cycles
of capecitabine versus observation—plus hormone therapy
in both arms for patients with hormone receptor–positive
tumors—and found a statistically significant increase in
DFS and OS with capecitabine. The effect was particularly
remarkable in TNBC. Compared with our trial, the pop-
ulations in both studies were significantly different, as
Asian patients had a significantly higher risk of relapse, as
shown by the 56.1% 5-year DFS for patients with TNBC in
the control arm of the CREATE-X trial. In contrast, DFS in
the control arm in our trial was better than expected: DFS
at 5 years was 76.8%, while our statistical hypothesis
assumed a 5-year DFS of 64.7% on the basis of historical
controls.
Moreover, the selection criteria in the CREATE-X trial
limited to patients with residual disease after neoadjuvant
treatment suggest that capecitabine could have a more
relevant role in patients with tumors that are less sensitive
or partially resistant to regimens containing anthracyclines
and taxanes.
The DFS events in our trial were numerically higher in the
control group (n = 120) than in the capecitabine group
(n = 105), arguably because of the apparent efficacy of
TABLE 4. Safety Profile According to Study Arm (safety population)
AEs Based on NCI-CTCAE v3.0 (AEs reported
in ‡ 5% globally)
Capecitabine Arm (n = 436), No. (%) Observation Arm (n = 425), No. (%)
Grade 1-4 Grade 3 Grade 4 Grade 1-4 Grade 3 Grade 4
Hand and foot syndrome 306.0 (70.2) 82.0 (18.8) — 3.0 (0.7) — —
Diarrhea 154.0 (35.3) 14.0 (3.2) 1.0 (0.2) 6.0 (1.4) — —
Nausea 103.0 (23.6) 4.0 (0.9) — 6.0 (1.4) — —
Vomiting 45.0 (10.3) 3.0 (0.7) — 2.0 (0.5) — —
Abdominal pain, general 27.0 (6.2) 1.0 (0.2) — 1.0 (0.2) — —
Any cardiac event, general 5.0 (1.1) 2.0 (0.5) — 4.0 (0.9) 1.0 (0.2) —
Fatigue 172.0 (39.44) 13.0 (3.0) — 48.0 (11.3) — —
Irregular menses 69.0 (15.8) 57.0 (13.1) — 67.0 (15.8) 55.0 (12.9) —
Hemoglobin decrease 107.0 (24.5) 1.0 (0.2) — 27.0 (6.4) — —
Leukocytes (total WBC) decrease 136.0 (31.2) 1.0 (0.2) — 58.0 (13.6) — —
Lymphopenia 63.0 (14.4) 3.0 (0.7) 1.0 (0.2) 33.0 (7.8) 1.0 (0.2) —
Neutrophils/granulocytes decrease 125.0 (28.7) 8.0 (1.8) — 46.0 (10.8) — —
Thrombocytopenia 22.0 (5.0) 1.0 (0.2) — 8.0 (1.9) — —
ALT, SGPT increase 85.0 (19.5) 1.0 (0.2) — 28.0 (6.6) — —
AST, SGOT increase 83.0 (19.0) — 1.0 (0.2) 23.0 (5.4) — —
Hyperbilirubinemia 52.0 (11.9) 2.0 (0.5) 1.0 (0.2) 2.0 (0.5) — —
Alkaline phosphatase increase 63.0 (14.4) — — 30.0 (7.1) — —
Hypercholesterolemia 34.0 (7.8) — — 35.0 (8.2) — —
Heartburn/dyspepsia 53.0 (12.2) — — 5.0 (1.2) — —
Nail changes 42.0 (9.6) 2.0 (0.5) — 3.0 (0.7) — —
Sensory neuropathy 66.0 (15.1) 3.0 (0.7) — 25.0 (5.9) 1.0 (0.2) —
Musculoskeletal pain (joint) 54.0 (12.4) 1.0 (0.2) — 29.0 (6.8) 1.0 (0.2) —
Musculoskeletal pain (muscle) 39.0 (8.9) 1.0 (0.2) — 9.0 (2.1) — —
Headache 43.0 (9.9) — — 7.0 (1.6) — —
Abbreviations: AE, adverse event; NCI-CTCAE v3.0, National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0;
SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.
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capecitabine in a predefined subgroup of patients—being
a stratification factor as well—with nonbasal phenotype,
as defined by central immunohistochemistry (lack of
staining for epidermal growth factor receptor and cyto-
keratins 5/6). In these patients, both DFS and OS were
statistically superior with capecitabine. TNBC is a het-
erogeneous disease that encompasses a wide spectrum of
clinical and molecular subtypes with different sensitivity to
standard therapies,11 The results in the nonbasal sub-
group suggest that the activity of capecitabine might be
selective for this particular subset of patients, although
a validation of this hypothesis in other TNBC adjuvant
trials exploring capecitabine is necessary to confirm the
finding. Perhaps capecitabine is less effective in basal-like
tumors as these are highly proliferative tumors and more
sensitive to taxanes carboplatin and eribulin, as seen in
the TNT trial comparing docetaxel with carboplatin12 and
the 301 study comparing eribulin with capecitabine,13
whereas nonbasal tumors could be more sensitive to an
antimetabolite drug, such as capecitabine, as they have
a lower proliferation index.
The tolerability of capecitabine was as expected, with
a median dose intensity of 86.3% and 75.2% of patients
receiving the planned 8 cycles of therapy.
Among the limitations of this trial, we can include the fact that
it was an open-label study. In addition, the population enrolled
demonstrated a much lower recurrence rate than expected.
The latter finding has been observed in other recent adjuvant
trials and compromises the ability to show a difference be-
tween treatment strategies. In contrast, designed in 2002 to
2003, this was one of the first trials, to our knowledge, devoted
to this specific subtype of breast cancer.
In conclusion, the GEICAM-CIBOMA study failed to show
a statistically significant improvement in DFS by adding
capecitabine to standard (neo)adjuvant chemotherapy for
operable TNBC. An apparent improvement in DFS and OS
was observed in the nonbasal subset of patients, although
the real implication of this finding should be further con-
firmed with the analysis of other (neo)adjuvant capecita-
bine trials.
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